FAQ: Lantern Pharma's FDA Meeting and Pediatric CNS Cancer Trial Guidance

What is the main announcement from Lantern Pharma?

Lantern Pharma completed a Type C meeting with the FDA and received guidance on the regulatory pathway and design of a planned pediatric trial targeting CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT).

What specific guidance did the FDA provide for the trial?

The FDA supported Lantern’s proposal for a parallel ATRT cohort and the potential inclusion of spironolactone as a combination agent with LP-184/STAR-001, the company’s lead investigational therapy.

When is the trial expected to begin?

Trial initiation is targeted for Q1 2026, following submission of an IND amendment reflecting the FDA feedback.

What designations does this program hold?

The program holds Rare Pediatric Disease and Orphan Drug designations, which provide certain regulatory and commercial benefits for treatments targeting rare conditions.

What outcomes will the multi-site study focus on?

The planned multi-site study will focus on progression-free survival, overall response rate, and quality-of-life outcomes for pediatric CNS cancer patients.

Who is conducting this trial?

Lantern Pharma, through its subsidiary Starlight Therapeutics, will conduct the trial. Lantern is an AI-driven clinical-stage oncology company that uses its RADR® platform for drug development.

Where can I find more information about Lantern Pharma?

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/AzoGl.

What is Lantern Pharma’s approach to drug development?

Lantern Pharma uses its proprietary AI and machine learning platform, RADR®, which leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate oncology drug discovery and development.